BLUE vs. ABBV
Compare and contrast key facts about bluebird bio, Inc. (BLUE) and AbbVie Inc. (ABBV).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BLUE or ABBV.
Correlation
The correlation between BLUE and ABBV is 0.44, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
BLUE vs. ABBV - Performance Comparison
Loading data...
Key characteristics
BLUE:
-0.56
ABBV:
0.82
BLUE:
-0.88
ABBV:
1.18
BLUE:
0.88
ABBV:
1.18
BLUE:
-0.83
ABBV:
1.10
BLUE:
-1.33
ABBV:
2.67
BLUE:
62.62%
ABBV:
8.52%
BLUE:
152.15%
ABBV:
27.67%
BLUE:
-99.89%
ABBV:
-45.09%
BLUE:
-99.89%
ABBV:
-11.46%
Fundamentals
BLUE:
$34.27M
ABBV:
$326.55B
BLUE:
-$24.84
ABBV:
$2.34
BLUE:
0.32
ABBV:
0.39
BLUE:
0.41
ABBV:
5.69
BLUE:
0.73
ABBV:
229.63
BLUE:
$65.23M
ABBV:
$57.37B
BLUE:
$1.72M
ABBV:
$44.44B
BLUE:
-$108.13M
ABBV:
$16.33B
Returns By Period
In the year-to-date period, BLUE achieves a -60.55% return, which is significantly lower than ABBV's 8.97% return. Over the past 10 years, BLUE has underperformed ABBV with an annualized return of -47.44%, while ABBV has yielded a comparatively higher 15.94% annualized return.
BLUE
-60.55%
-36.12%
-59.41%
-84.48%
-66.16%
-47.44%
ABBV
8.97%
9.58%
11.01%
22.54%
21.38%
15.94%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
BLUE vs. ABBV — Risk-Adjusted Performance Rank
BLUE
ABBV
BLUE vs. ABBV - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for bluebird bio, Inc. (BLUE) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
BLUE vs. ABBV - Dividend Comparison
BLUE has not paid dividends to shareholders, while ABBV's dividend yield for the trailing twelve months is around 3.36%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BLUE bluebird bio, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ABBV AbbVie Inc. | 3.36% | 3.49% | 3.82% | 3.49% | 3.84% | 4.41% | 4.83% | 3.89% | 2.65% | 3.64% | 3.41% | 2.54% |
Drawdowns
BLUE vs. ABBV - Drawdown Comparison
The maximum BLUE drawdown since its inception was -99.89%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for BLUE and ABBV. For additional features, visit the drawdowns tool.
Loading data...
Volatility
BLUE vs. ABBV - Volatility Comparison
bluebird bio, Inc. (BLUE) has a higher volatility of 22.75% compared to AbbVie Inc. (ABBV) at 9.61%. This indicates that BLUE's price experiences larger fluctuations and is considered to be riskier than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
BLUE vs. ABBV - Financials Comparison
This section allows you to compare key financial metrics between bluebird bio, Inc. and AbbVie Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BLUE vs. ABBV - Profitability Comparison
BLUE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, bluebird bio, Inc. reported a gross profit of 15.73M and revenue of 38.52M. Therefore, the gross margin over that period was 40.8%.
ABBV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, AbbVie Inc. reported a gross profit of 11.20B and revenue of 13.34B. Therefore, the gross margin over that period was 83.9%.
BLUE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, bluebird bio, Inc. reported an operating income of -36.46M and revenue of 38.52M, resulting in an operating margin of -94.6%.
ABBV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, AbbVie Inc. reported an operating income of 3.73B and revenue of 13.34B, resulting in an operating margin of 28.0%.
BLUE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, bluebird bio, Inc. reported a net income of -28.71M and revenue of 38.52M, resulting in a net margin of -74.5%.
ABBV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, AbbVie Inc. reported a net income of 1.29B and revenue of 13.34B, resulting in a net margin of 9.6%.